A time-course study of behavioral and electrophysiological characteristics in a mouse model of different stages of Parkinson's disease using 6-hydroxydopamine

Behavioural Brain Research

Volumn 284, Issue , 2015, Pages 153-157

  Park, Sunghee Estelle ^a,b   Song, Kang Il ^a,c   Suh, Jun Kyo Francis ^a   Hwang, Dosik ^c   Youn, Inchan ^a,d  

^a Korea Institute of Science and Technology   (South Korea)

^b Korea University   (South Korea)

^c Yonsei University   (South Korea)

^d University of Science and Technology (UST)   (South Korea)

Author keywords

6 Hydroxydopamine; Parkinson's disease; Staged mouse model; Subthalamic nucleus; TH immunohistochemistry

Indexed keywords

OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE;

ADULT; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL LOSS; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DOPAMINERGIC NERVE CELL; ELECTROPHYSIOLOGY; HEAD MOVEMENT; MALE; MOTOR DYSFUNCTION; MOUSE; NERVE CELL DEGENERATION; NERVE CONDUCTION; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SUBSTANTIA NIGRA PARS COMPACTA; SUBTHALAMIC NUCLEUS; ACTION POTENTIAL; ANIMAL; BODY WEIGHT; C57BL MOUSE; IMMUNOHISTOCHEMISTRY; MEDIAL FOREBRAIN BUNDLE; METABOLISM; MICROELECTRODE; MOTOR ACTIVITY; NERVE CELL; PARKINSONISM; PATHOLOGY; PHYSIOLOGY;

ACTION POTENTIALS; ANIMALS; BODY WEIGHT; DISEASE PROGRESSION; IMMUNOHISTOCHEMISTRY; MALE; MEDIAL FOREBRAIN BUNDLE; MICE, INBRED C57BL; MICROELECTRODES; MOTOR ACTIVITY; NEURONS; OXIDOPAMINE; PARKINSONIAN DISORDERS; PARS COMPACTA; SUBTHALAMIC NUCLEUS; TYROSINE 3-MONOOXYGENASE;

EID: 84923369723     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2015.02.019     Document Type: Article

References (24)

1. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39:889-909.
2. Fahn S. Description of Parkinson's disease as a clinical syndrome. Ann N Y Acad Sci 2003, 991:1-14.
3. DeLong M.R. Primate models of movement disorders of basal ganglia origin. TINS 1990, 13:281-285.
4. Benabid A.L., Chabardes S., Mitrofanis J., Pollak P. Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease. Lancet Neurol 2009, 8:67-81.
5. Benazzouz A., Gross C., Feger J., Boraud Th Bioulac B. Reversal of rigidity and improvement in motor performance by subthalamic high-frequency stimulation in MPTP-treated monkeys. Eur J Neurosci 1993, 5:382-389.
6. Deumens R., Blokland A., Prickaerts J. Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol 2002, 175:303-317.
7. Ungerstedt U., Arbuthnott G.W. Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res 1970, 24:485-493.
8. Truong L., Allbutt H., Kassiou M., Henderson J.M. Developing a preclinical model of Parkinson's disease: a study of behavior in rats with graded 6-OHDA lesions. Behav Brain Res 2006, 169:1-9.
9. Korecka J.A., Eggers R., Swaab D.F., Bossers K., Verhaagen J. Modeling early Parkinson's disease pathology with chronic low dose MPTP treatment. Restor Neurol Neuros 2013, 31:155-167.
10. Schober A. Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell Tissue Res 2004, 318:215-224.
11. Remple M.S., Bradenham C.H., Kao C.C., Charles P.D., Neimat J.S., Konrad P.E. Subthalamic nucleus neuronal firing rate increases with Parkinson's disease progression. Movement Disord 2011, 26:1657-1662.
12. Paxinos G., Franklin K.B.J. The mouse brain in stereotaxic coordinates 2001, Academic Press, CA. 2nd ed.
13. Schallert T., Tillerson J.L. Intervention strategies for degeneration of dopamine neurons in Parkinsonism: optimizing behavioral assessment of outcome. Central nervous system diseases 2000, 131-151. Humana Press, NJ. D.F. Emerich, R.L. Dean, P.R. Sanberg (Eds.).
14. Iancu R., Mohapel P., Brundin P., Paul G. Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice. Behav Brain Res 2005, 162:1-10.
15. Henderson J.M., Watson S., Halliday G.M., Heinemann T., Gerlach M. Relationships between various behavioural abnormalities and nigrostriatal dopamine depletion in the unilateral 6-OHDA-lesioned rat. Behav Brain Res 2003, 139:105-113.
16. Borlongan C.V., Sanberg P.R. Elevated body swing test: a new behavioral parameter for rats with 6-hydroxydopamine-induced hemiparkinsonism. J Neurosci 1995, 15:5372-5378.
17. Kirik D., Rosenblad C., Bjorklund A. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp Neurol 1998, 152:259-277.
18. Hoehn M.M., Yahr M.D. Parkinsonism: onset, progression, and mortality. Neurology 1967, 17:427-442.
19. Vieregge P., Stolze H., Klein C., Heberlein I. Gait quantitation in Parkinson's disease-locomotor disability and correlation to clinical rating scales. J Neural Transm 1997, 104:237-248.
20. Blandini F., Armentero M., Martignoni E. The 6-hydroxydopamine model: news from the past. Parkinsonism Relat Disord 2008, 14:S124-S129.
21. Carman L.S., Gage F.H., Shults C.W. Partial lesion of the substantia nigra: relation between extent of lesion and rotational behavior. Brain Res 1991, 553:275-283.
22. Hudson J.L., van Horne C.G., Stromberg I., Brock S., Clayton J., Masserano J., et al. Correlation of apomorphine- and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats. Brain Res 1993, 626:167-174.
23. Vila M., Perier C., Feger J., Yelnik J., Faucheux B., Ruberg M., et al. Evolution of changes in neuronal activity in the subthalamic nucleus of rats with unilateral lesion of the substantia nigra assessed by metabolic and electrophysiological measurements. Eur J Neurosci 2000, 12:337-344.
24. Bergman H., Wichmann T., Karmon B., DeLong M.R. The primate subthalamic nucleus, II. Neuronal activity in the MPTP model of Parkinsonism. J Neurophysiol 1994, 72:507-520.